Panitumumab is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Panitumumab becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Information about SaveRxCanada.to
List of countries where we can ship Panitumumab:
Latest news releases on Panitumumab:
NEJM Journal Watch Concise summaries and expert physician commentary that busy clinicians need to enhance patient care. NEJM Knowledge + The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams.
Vectibix® (panitumumab) is for treating patients with wild-type RAS metastatic colorectal cancer (cancer that has spread outside of the colon and rectum).
Vectibix (panitumumab) is a cancer medication that interferes with the growth and spread of cancer cells in the body. Vectibix is used to treat a certain type of metastatic colorectal cancer that has progressed after treatment with other chemotherapy.
are a late manifestation with EGFR inhibitors, usually starting 4-8 weeks after therapy initiation. Nails are reportedly more brittle and may crack, and tend to grow more slowly.
The supportive therapies (e.g. antiemetics, premedications, etc.), infusion times, diluents, volumes and routes of administration, if included, are listed as defaults.
Learn about Vectibix® (panitumumab) dosing and administration information, and find dose modifications for dermatologic toxicity.
Each mL of concentrate contains 20 mg panitumumab. Each single-use vial contains either 100 mg of panitumumab in 5 mL, or 400 mg of panitumumab in 20 mL.
This content is made available for your personal use, educational advancement, or professional development. Unauthorized reproduction is prohibited.